1. Scrip
  2. >>Business

Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent

Skyclarys From Reata A More Immediate Revenue Source

 
• By Mandy Jackson

CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.

Climb to success - Man working hard and climbing to reach the top of hill
Leqembi and other new products will be slow to add revenue growth • Source: Shutterstock

Biogen, Inc. CEO Chris Viehbacher made a plea for patience while the Leqembi (lecanemab) launch slowly builds momentum as health care providers gear up to administer the anti-amyloid therapy and monitor early Alzheimer’s disease patients treated with the Eisai Co., Ltd.-partnered product. However, investors have been waiting years now for Biogen to return to sales growth and a significant near-term upswing in revenue does not appear to be on the horizon.

Key Takeaways

  • Biogen reported a 1% overall revenue increase driven by manufacturing and other revenue, but product sales fell 2.9%.

  • The company gained full approval for...

The company reported its third quarter sales and earnings on 8 November, including $2m in Q3 sales for Leqembi. Biogen’s total Q3 revenue increased 1% year-over-year to $2.53bn, but a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

More from Scrip

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.